This company listing is no longer active
1N7 Stock Overview
A medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Nevro Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.30 |
| 52 Week High | US$12.50 |
| 52 Week Low | US$3.16 |
| Beta | 0.82 |
| 1 Month Change | -0.93% |
| 3 Month Change | 49.72% |
| 1 Year Change | -56.20% |
| 3 Year Change | -92.37% |
| 5 Year Change | -94.67% |
| Change since IPO | -73.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1N7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.9% | 4.7% | 0.8% |
| 1Y | -56.2% | -8.9% | 14.6% |
Return vs Industry: 1N7 underperformed the German Medical Equipment industry which returned -14% over the past year.
Return vs Market: 1N7 underperformed the German Market which returned 9% over the past year.
Price Volatility
| 1N7 volatility | |
|---|---|
| 1N7 Average Weekly Movement | 10.3% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 1N7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1N7's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,099 | Kevin Thornal | nevro.com |
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system.
Nevro Corp. Fundamentals Summary
| 1N7 fundamental statistics | |
|---|---|
| Market cap | €200.73m |
| Earnings (TTM) | -€102.93m |
| Revenue (TTM) | €370.69m |
0.5x
P/S Ratio-2.0x
P/E RatioIs 1N7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1N7 income statement (TTM) | |
|---|---|
| Revenue | US$408.52m |
| Cost of Revenue | US$138.99m |
| Gross Profit | US$269.53m |
| Other Expenses | US$382.97m |
| Earnings | -US$113.44m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.99 |
| Gross Margin | 65.98% |
| Net Profit Margin | -27.77% |
| Debt/Equity Ratio | 97.7% |
How did 1N7 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/04 05:10 |
| End of Day Share Price | 2025/04/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nevro Corp. is covered by 9 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joanne Wuensch | BMO Capital Markets Equity Research |
| Gregory Chodaczek | B. Riley Securities, Inc. |
| David Turkaly | Citizens JMP Securities, LLC |